Lena Osswald

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Correction: Strong constitutive NF-κB signaling in B cells drives SLL/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.

Correction: Strong constitutive NF-κB signaling in B cells drives SLL/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.

Journal: Leukemia
Published: February 11, 2026

Serous Cavity Mast Cells Depend on the ROQUIN Paralogs.

Serous Cavity Mast Cells Depend on the ROQUIN Paralogs.

Journal: European journal of immunology
Published: April 29, 2025

Strong constitutive NF-κB signaling in B cells drives SLL/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.

Strong constitutive NF-κB signaling in B cells drives SLL/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.

Journal: Leukemia
Published: February 21, 2025

Hyperreactive B cells instruct their elimination by T cells to curb autoinflammation and lymphomagenesis.

Hyperreactive B cells instruct their elimination by T cells to curb autoinflammation and lymphomagenesis.

Journal: Immunity
Published: February 21, 2024

Letermovir Prophylaxis for CMV Reactivation in Allogeneic Stem Cell Recipients: A Retrospective Single Center Analysis.

Letermovir Prophylaxis for CMV Reactivation in Allogeneic Stem Cell Recipients: A Retrospective Single Center Analysis.

Journal: Anticancer research
Published: August 15, 2022

Oncogenic KrasG12D Activation in the Nonhematopoietic Bone Marrow Microenvironment Causes Myelodysplastic Syndrome in Mice.

Oncogenic KrasG12D Activation in the Nonhematopoietic Bone Marrow Microenvironment Causes Myelodysplastic Syndrome in Mice.

Journal: Molecular cancer research : MCR
Published: March 25, 2020

Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation.

Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation.

Journal: Nature communications
Published: September 07, 2019

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Journal: Nature medicine
Published: April 11, 2018

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Journal: Nature medicine
Published: July 10, 2016
Showing 1-9 of 9

Last Updated: 09/26/2026